Wagh Vishal, Urhekar Anant, Modi Deepak
Department of Microbiology, MGM Institute of Health Sciences, Kamothe, Navi Mumbai, 410209, India.
Molecular and Cellular Biology Laboratory, National Institute for Research in Reproductive Health, J.M. Street, Parel, Mumbai, 400012, India.
Tuberculosis (Edinb). 2017 Jan;102:24-30. doi: 10.1016/j.tube.2016.10.007. Epub 2016 Nov 1.
Identification of blood biomarkers that can be useful for predicting Mycobacterium tuberculosis (M.TB) infection, effect of therapy and Multi Drug Resistant (MDR) TB infected individuals is clinically useful for combating tuberculosis epidemic. In this study, we have evaluated the levels of selected miRNAs in serum of TB and MDR TB patients. In addition, we have studied their levels in serum of patients post-therapy. The levels of 4-miRNAs (miR-16, miR-29a, miR-125b and miR-155) were measured in 30 newly diagnosed TB patients, 19 Multi Drug Resistant (MDR) TB patients, 10 patients who completed TB therapy and were TB negative. 30 healthy individuals were recruited as controls. The levels of the miRNAs were estimated by qRT-PCR. Of the four miRNAs studied, the levels of miR-16 were significantly elevated and miR-155 were significantly reduced in serum of TB patients as compared to uninfected controls. The Receiver Operating Characteristic (ROC) curve of miR-16 and miR-155 exhibited a significant distinguishing efficiency with an AUC value of 1 (95% CI, 1 to 1) and 0.967 (95% CI, 0.92-1.04) respectively. Following the therapy, the levels of miR-16 and miR-155 returned to those observed in healthy subjects. In patients with MDR TB, miR-155 was lower as compared to healthy controls and TB treated group but higher as compared to TB naïve patients. miR-16 levels were lowest in serum of MDR TB patients compared to TB naïve, TB treated group and healthy controls. In conclusion, miR-16 and miR-155 in serum may act as surrogate biomarker for studying TB infection, progression of therapy and MDR TB.
鉴定可用于预测结核分枝杆菌（M.TB）感染、治疗效果以及耐多药（MDR）结核病感染个体的血液生物标志物，对于抗击结核病流行具有临床意义。在本研究中，我们评估了结核病患者和耐多药结核病患者血清中所选miRNA的水平。此外，我们还研究了治疗后患者血清中这些miRNA的水平。在30例新诊断的结核病患者、19例耐多药结核病患者、10例完成结核病治疗且结核检测呈阴性的患者中测量了4种miRNA（miR-16、miR-29a、miR-125b和miR-155）的水平。招募了30名健康个体作为对照。通过qRT-PCR估算miRNA的水平。在所研究的4种miRNA中，与未感染的对照相比，结核病患者血清中miR-16的水平显著升高，miR-155的水平显著降低。miR-16和miR-155的受试者工作特征（ROC）曲线分别显示出显著的区分效率，AUC值分别为1（95%CI，1至1）和0.967（95%CI，0.92 - 1.04）。治疗后，miR-16和miR-155的水平恢复到健康受试者中观察到的水平。在耐多药结核病患者中，与健康对照和结核病治疗组相比，miR-155较低，但与未感染结核病的患者相比更高。与未感染结核病的患者、结核病治疗组和健康对照相比，耐多药结核病患者血清中miR-16的水平最低。总之，血清中的miR-16和miR-155可能作为研究结核病感染、治疗进展和耐多药结核病的替代生物标志物。
